InvestorsHub Logo
Followers 2
Posts 118
Boards Moderated 0
Alias Born 05/31/2011

Re: None

Wednesday, 11/21/2018 8:48:54 AM

Wednesday, November 21, 2018 8:48:54 AM

Post# of 34625
Marker Therapeutics (MRKR) gets a new Buy rating and $16 price target at Nomura this morning. Nomura's analyst 'believes the company's MultiTAA platform, which selects for and expands patient tumor-specific T cells by directly presenting a blend of tumor-associated antigens and cytokines in vitro, is "amenable to rapid approval." Further, Marker is trading at a discount to immunotherapy peers despite offering a "strong" de-risking data flow that will likely result in share upside over the next 12 months'


https://seekingalpha.com/instablog/498952-bret-jensen/5239075-4-notable-thanksgiving-analyst-calls
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News